Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.

Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schluep M, Du Pasquier RA.

Mult Scler. 2014 Jun;20(7):837-42. doi: 10.1177/1352458513513208. Epub 2013 Nov 20.

PMID:
24258149
2.

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.

Simioni S, Cavassini M, Annoni JM, Métral M, Iglesias K, Rimbault Abraham A, Jilek S, Calmy A, Müller H, Fayet-Mello A, Giacobini E, Hirschel B, Du Pasquier RA.

Neurology. 2013 Feb 5;80(6):553-60. doi: 10.1212/WNL.0b013e3182815497. Epub 2013 Jan 23.

PMID:
23345635
3.

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

Antoniol C, Jilek S, Schluep M, Mercier N, Canales M, Le Goff G, Campiche C, Pantaleo G, Du Pasquier RA.

Neurology. 2012 Dec 4;79(23):2258-64. doi: 10.1212/WNL.0b013e3182768983. Epub 2012 Nov 21.

PMID:
23175722
4.

Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy.

Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, Cusini A, Günthard HF, Cavassini M, Vernazza PL; Swiss HIV Cohort Study.

AIDS. 2013 Jan 14;27(2):203-10. doi: 10.1097/QAD.0b013e32835a9a4a.

PMID:
23032410
5.

MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects.

Jilek S, Schluep M, Pantaleo G, Du Pasquier RA.

Neurol Sci. 2013 Apr;34(4):539-43. doi: 10.1007/s10072-012-1144-4. Epub 2012 Jun 30.

PMID:
22752855
6.

HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis.

Jilek S, Schluep M, Harari A, Canales M, Lysandropoulos A, Zekeridou A, Pantaleo G, Du Pasquier RA.

J Immunol. 2012 May 1;188(9):4671-80. doi: 10.4049/jimmunol.1103100. Epub 2012 Mar 28.

7.

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.

Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, Staugaitis SM, Welch W, Jilek S, Du Pasquier RA, Brück W, Toyka KV, Ransohoff RM, Wiendl H.

Neurology. 2012 Feb 14;78(7):458-67; discussion 465. doi: 10.1212/WNL.0b013e3182478d4b. Epub 2012 Feb 1.

8.

Immunological and clinical consequences of treating a patient with natalizumab.

Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H.

Mult Scler. 2012 Mar;18(3):335-44. doi: 10.1177/1352458511421919. Epub 2011 Sep 9.

PMID:
21908480
9.

Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects.

Lysandropoulos AP, Jaquiéry E, Jilek S, Pantaleo G, Schluep M, Du Pasquier RA.

J Neuroimmunol. 2011 Apr;233(1-2):240-4. doi: 10.1016/j.jneuroim.2010.11.008. Epub 2010 Dec 24.

PMID:
21186064
10.

Cytokine mRNA profile of Epstein-Barr virus-stimulated highly differentiated T cells in multiple sclerosis: a pilot study.

Jaquiéry E, Jilek S, Schluep M, Le Goff G, Garcia M, Pantaleo G, Du Pasquier RA.

J Neuroimmunol. 2010 Aug 25;225(1-2):167-70. doi: 10.1016/j.jneuroim.2010.04.011. Epub 2010 May 15.

PMID:
20471696
11.

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.

Jilek S, Jaquiéry E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA.

Lancet Neurol. 2010 Mar;9(3):264-72. doi: 10.1016/S1474-4422(10)70006-5. Epub 2010 Jan 29.

PMID:
20117055
12.

Intrathecal immune responses to EBV in early MS.

Jaquiéry E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, Pantaleo G, Du Pasquier RA.

Eur J Immunol. 2010 Mar;40(3):878-87. doi: 10.1002/eji.200939761. Erratum in: Eur J Immunol. 2011 May;41(5):1501.

13.

Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.

Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, Kleeberg J, Le Goff G, Pantaleo G, Du Pasquier RA.

Brain. 2008 Jul;131(Pt 7):1712-21. doi: 10.1093/brain/awn108. Epub 2008 Jun 11.

PMID:
18550621
14.

Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response.

Jilek S, Kuhle J, Meylan P, Reichhart MD, Pantaleo G, Du Pasquier RA.

J Neuroimmunol. 2007 Dec;192(1-2):192-7. Epub 2007 Nov 5.

PMID:
17980440
15.

CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis.

Jilek S, Schluep M, Rossetti AO, Guignard L, Le Goff G, Pantaleo G, Du Pasquier RA.

Clin Immunol. 2007 Apr;123(1):105-13. Epub 2006 Dec 22.

PMID:
17188575
16.

DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells.

Jilek S, Merkle HP, Walter E.

Adv Drug Deliv Rev. 2005 Jan 10;57(3):377-90. Review.

PMID:
15560947
17.

Modulation of allergic responses in mice by using biodegradable poly(lactide-co-glycolide) microspheres.

Jilek S, Walter E, Merkle HP, Corthésy B.

J Allergy Clin Immunol. 2004 Oct;114(4):943-50.

PMID:
15480340
18.

Transfection of a mouse dendritic cell line by plasmid DNA-loaded PLGA microparticles in vitro.

Jilek S, Zurkaulen H, Pavlovic J, Merkle HP, Walter E.

Eur J Pharm Biopharm. 2004 Nov;58(3):491-9.

PMID:
15451523
19.
20.

Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles.

Kempf M, Mandal B, Jilek S, Thiele L, Vörös J, Textor M, Merkle HP, Walter E.

J Drug Target. 2003 Jan;11(1):11-8.

PMID:
12852436
21.

Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?

Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E.

J Control Release. 2001 Sep 11;76(1-2):59-71.

PMID:
11532313
22.

Supplemental Content

Support Center